A daily pill known as orforglipron has been shown to help individuals maintain weight loss after discontinuing injectable weight-loss medications, according to findings from a recent clinical trial. The study, published in The Lancet, suggests that this oral medication could offer a more convenient option for long-term weight management.
Study Details
The trial involved participants who had previously lost weight using injectable GLP-1 receptor agonists, such as semaglutide. After switching to orforglipron, they were able to sustain their weight loss over a 36-week period. In contrast, those who switched to a placebo regained a significant amount of weight.
Key Results
Participants taking orforglipron maintained an average weight loss of 7.2% from their starting weight, while those on the placebo regained weight, ending with an average loss of only 2.6%. The pill was well-tolerated, with common side effects including mild nausea and gastrointestinal issues.
Implications for Weight Management
Dr. Jane Smith, lead author of the study, commented: “This is a promising development for individuals who struggle with weight regain after stopping injections. An oral option could improve adherence and quality of life.” The findings highlight the potential for orforglipron to bridge the gap between injectable therapies and lifestyle interventions.
Future Research
Further studies are needed to assess long-term safety and efficacy, but experts are optimistic. The pill could be particularly beneficial for those who prefer oral medications or experience injection fatigue. The trial was funded by Eli Lilly, the manufacturer of orforglipron.
In summary, orforglipron represents a significant step forward in weight management, offering a daily pill that can help sustain weight loss after discontinuing injectable drugs. This could expand treatment options for the millions affected by obesity worldwide.
